Applied Biosystems and its joint venture partner, MDS Analystical Technologies, this week said they plan to commercialize the FlashQuant mass spectrometry platform for drug compound screening. MDS Analytical Technologies was formed when MDS acquired Molecular Devices in March then combined it with MDS Sciex.
Â
FlashQuant is expected to be the first commercially available system combining triple-quadrupole MS with MALDI technology, the companies said in a statement. In tests with the platform, it delivered a 25-fold increase in speed for small-molecule quantitation, compared to the fastest liquid chromatography-coupled triple-quadrupole mass specs currently on the market, the companies said.
Â
Â
Anaspec last week launched 69 new antibodies. They include Anti-Wilm's Tumor Protein, Melanoma, and Anti-Renal Cell Carcinoma.